Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer

被引：0
|
作者：
Takeshi Suzuki
Eiji Shinozaki
Hiroki Osumi
Izuma Nakayama
Yumiko Ota
Takashi Ichimura
Mariko Ogura
Takeru Wakatsuki
Akira Ooki
Daisuke Takahari
Mitsukuni Suenaga
Keisho Chin
Kensei Yamaguchi
机构：
[1] The Cancer Institute Hospital,Department of Gastroenterology
[2] Japanese Foundation for Cancer Research,Division of Gastroenterology and Hepatology, Department of Internal Medicine
[3] Keio University School of Medicine,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词：
Anti-VEGF; RAM; Bevacizumab-naïve; EGFR; Colorectal cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：307 / 313
页数：6
相关论文
共 50 条
  • [1] Second-line FOLFIRI plus ramucirumab with or without prior bevacizumab for patients with metastatic colorectal cancer
    Suzuki, Takeshi
    Shinozaki, Eiji
    Osumi, Hiroki
    Nakayama, Izuma
    Ota, Yumiko
    Ichimura, Takashi
    Ogura, Mariko
    Wakatsuki, Takeru
    Ooki, Akira
    Takahari, Daisuke
    Suenaga, Mitsukuni
    Chin, Keisho
    Yamaguchi, Kensei
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (02) : 307 - 313
  • [2] Predictors of the Efficacy of FOLFIRI plus Bevacizumab as Second-Line Treatment in Metastatic Colorectal Cancer Patients
    Suenaga, Mitsukuni
    Matsusaka, Satoshi
    Ueno, Masashi
    Yamamoto, Noriko
    Shinozaki, Eiji
    Mizunuma, Nobuyuki
    Yamaguchi, Toshiharu
    Hatake, Kiyohiko
    [J]. SURGERY TODAY, 2011, 41 (08) : 1067 - 1074
  • [3] Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients
    Mitsukuni Suenaga
    Satoshi Matsusaka
    Masashi Ueno
    Noriko Yamamoto
    Eiji Shinozaki
    Nobuyuki Mizunuma
    Toshiharu Yamaguchi
    Kiyohiko Hatake
    [J]. Surgery Today, 2011, 41 : 1067 - 1074
  • [4] Metastatic colorectal Cancer Ramucirumab plus FOLFIRI as Second Line Treatment
    Lichert, Frank
    [J]. ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2015, 53 (10): : 1145 - 1145
  • [5] Safety and Pharmacokinetics of Second-line Ramucirumab plus FOLFIRI in Japanese Patients with Metastatic Colorectal Carcinoma
    Yoshino, Takayuki
    Yamazaki, Kentaro
    Gotoh, Masahiro
    Nasroulah, Federico
    Gao, Ling
    Yoshizuka, Naoto
    Ohtsu, Atsushi
    [J]. ANTICANCER RESEARCH, 2015, 35 (07) : 4003 - 4007
  • [6] Efficacy of ramucirumab in combination with second-line or salvage-line FOLFIRI in patients with metastatic colorectal cancer
    Katata, Y.
    Nagasaka, T.
    Tanioka, H.
    Nyuya, A.
    Toshima, T.
    Mori, Y.
    Shigeyasu, K.
    Okawaki, M.
    Yamamura, M.
    Tsuruta, A.
    Ueno, T.
    Yamaguchi, Y.
    [J]. ANNALS OF ONCOLOGY, 2018, 29 : 33 - 33
  • [7] Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer
    Matsubara, Yuki
    Masuishi, Toshiki
    Ogata, Takatsugu
    Nakazawa, Taiko
    Kato, Kyoko
    Nozawa, Kazuki
    Narita, Yukiya
    Honda, Kazunori
    Bando, Hideaki
    Taniguchi, Hiroya
    Kadowaki, Shigenori
    Ando, Masashi
    Tajika, Masahiro
    Muro, Kei
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (03) : 1123 - 1129
  • [8] Impact of omitting fluorouracil from FOLFIRI plus bevacizumab as second-line chemotherapy for patients with metastatic colorectal cancer
    Yuki Matsubara
    Toshiki Masuishi
    Takatsugu Ogata
    Taiko Nakazawa
    Kyoko Kato
    Kazuki Nozawa
    Yukiya Narita
    Kazunori Honda
    Hideaki Bando
    Hiroya Taniguchi
    Shigenori Kadowaki
    Masashi Ando
    Masahiro Tajika
    Kei Muro
    [J]. Journal of Cancer Research and Clinical Oncology, 2023, 149 : 1123 - 1129
  • [9] Impact of omitting fluorouracil from FOLFIRI plus bevacizumab in second-line treatment of metastatic colorectal cancer
    Matsubara, Yuki
    Masuishi, Toshiki
    Ogata, Takatsugu
    Nakazawa, Taiko
    Kato, Kyoko
    Nozawa, Kazuki
    Narita, Yukiya
    Honda, Kazunori
    Bando, Hideaki
    Kadowaki, Shigenori
    Ando, Masashi
    Tajika, Masahiro
    Muro, Kei
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S321 - S321
  • [10] Axitinib or bevacizumab (bev) plus FOLFOX or FOLFIRI as second-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)
    Bendell, J. C.
    Tournigand, C.
    Bednarczyk, M.
    Swieboda-Sadlej, A.
    Chung, I.
    Barone, C.
    Tarazi, J. C.
    Rosbrook, B.
    Ricart, A. D.
    Sobrero, A. F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
12345